—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Biogen Inc (BIIB) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for BIIB, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.42 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How BIIB has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.42 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Biogen Inc moved 0.42% on average · correlation 0.11 · higher than 42% of US names
  • Beta, last 3 months 0.80 more rate-sensitive lately than over the year
  • On the 10 worst bond days +0.33% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.51% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - General · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against BIIB on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Biogen Inc

BIIB in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Biogen discovers, develops and sells medicines for neurological, immune and rare conditions, largely outside the AI-linked sectors the diary tracks. Its portfolio includes multiple sclerosis treatments such as Tecfidera and Tysabri, the Alzheimer's drug Leqembi, and biosimilar versions of established antibody therapies. It partners with other drug developers, including Eisai and Ionis, to bring several of these medicines to market. The company is headquartered in Cambridge, Massachusetts.
Where it sits in the stack
Biogen carries no seat in Rubin or Halo, our AI-linked indices, so it sits outside the AI build-out stack the diary maps. It belongs instead to the pharmaceutical sleeve of the wider Closelooknet universe, tracked for its own sector dynamics rather than any layer of chip or data-centre supply.
Who it is priced against
Closelooknet has not set a peer group for Biogen; within our universe it sits among large-cap drug makers focused on neurology and immunology. The comparison the market often draws is with Eli Lilly, though the two differ in therapeutic focus and scale.
Why Closelooknet tracks it
Biogen holds a seat in the S&P 500 but no place in Rubin or Halo, and it does not carry a Closelooknet score. It does not appear in the diary's regular editions or quotes, since coverage there follows the AI-linked names.
What the diary watches
The diary watches whether Leqembi's uptake and the neurology and rare-disease pipeline shift Biogen's earnings mix over time.

Biogen Inc (BIIB) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 3 analyst actions on the wire · latest: price target by Buy by Stifel After Investor Meeting, 2026-09-10

The Street on this name

Analyst actions and the latest print for BIIB from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Buy by Stifel After Investor Meeting — target 242 Target set to $242 (+12.7% to spot) 2026-09-10
  • Price target RBC Capital — target 260 from 240 Target raised to $260 from $240 (+19.2% to spot) 2026-08-25
  • Initiation Wolfe Research — at Outperform Initiated to Outperform from Outperform 2026-08-18

3 actions on the analyst wire since 2026-08-13: 1 initiation, 2 target changes. Analyst wire → · Earnings wire →

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Biogen Inc (BIIB)?

Biogen Inc trades as BIIB on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is BIIB in a Closelooknet index?

Not currently — Biogen Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does BIIB trade against its moving averages?

Uptrend stack intact: Trades +6.9% vs the 50-day and +17.4% vs the 200-day average, 0.7% below the 52-week high and +68.1% off the 52-week low. Computed from daily closes. As of 2026-09-25 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Biogen Inc trade when bond yields rise?

Over the past year Biogen Inc had a beta of 0.42 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 42% of US names. On the 10 sessions in which long bonds fell most it moved +0.33% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Biogen Inc do?

Biogen discovers, develops and sells medicines for neurological, immune and rare conditions, largely outside the AI-linked sectors the diary tracks. Its portfolio includes multiple sclerosis treatments such as Tecfidera and Tysabri, the Alzheimer's drug Leqembi, and biosimilar versions of established antibody therapies. It partners with other drug developers, including Eisai and Ionis, to bring several of these medicines to market. Closelooknet has not set a peer group for Biogen; within our universe it sits among large-cap drug makers focused on neurology and immunology. The comparison the market often draws is with Eli Lilly, though the two differ in therapeutic focus and scale.

Where does Biogen Inc sit in the AI build-out?

Biogen carries no seat in Rubin or Halo, our AI-linked indices, so it sits outside the AI build-out stack the diary maps. It belongs instead to the pharmaceutical sleeve of the wider Closelooknet universe, tracked for its own sector dynamics rather than any layer of chip or data-centre supply. Biogen holds a seat in the S&P 500 but no place in Rubin or Halo, and it does not carry a Closelooknet score. It does not appear in the diary's regular editions or quotes, since coverage there follows the AI-linked names.

What has Wall Street done on Biogen Inc recently?

The most recent analyst action on Biogen Inc on the Closelooknet wire is a price target by Buy by Stifel After Investor Meeting on 2026-09-10 (target 242). 3 actions on the analyst wire since 2026-08-13: 1 initiation, 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BIIB, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.